Dr. Rhonda Patrick: Let us discuss omega-3, vitamin D, and exercise. Many U.S. adults consume less seafood and EPA plus DHA than recommended. That does not mean 90 percent have a diagnosed omega-3 deficiency.

Observational studies have linked higher omega-3 exposure with slower epigenetic aging. A more rigorous analysis came from DO-HEALTH, a randomized factorial trial in generally healthy European adults aged 70 or older.

Dr. Steve Horvath: The epigenetic analysis included 777 Swiss participants with blood samples at baseline and three years. The interventions were one gram per day of algae-derived omega-3, containing 330 milligrams EPA and 660 milligrams DHA; 2,000 IU per day of vitamin D3 or placebo; and a 30-minute home strength program three times weekly or a flexibility control.

The trial did not randomize 2,000 IU against 800 IU. Participants could use background vitamin D up to 800 IU per day, but the randomized comparison was 2,000 IU versus placebo.

Omega-3 produced small favorable changes in three of four newer DNA-methylation aging measures: PCPhenoAge, GrimAge2, and DunedinPACE. It did not affect PCGrimAge, and no intervention changed first-generation Horvath or Hannum clocks.

Vitamin D and the home strength program did not change the clocks alone. The full combination produced the largest result on PCPhenoAge, equivalent arithmetically to about 3.8 months over three years. The additive pattern did not appear consistently across the other clocks. This was intervention layering, not an omega-3 dose-response test.

Dr. Rhonda Patrick: The participants were generally healthy and active. Approximately 88 percent were physically active at baseline, and most were not vitamin-D deficient. That may limit the room for improvement and the generalizability of the results.

Separate DO-HEALTH analyses reported 39-percent lower odds of becoming prefrail with all three interventions, but no significant reduction in frailty itself. An exploratory cancer analysis reported fewer invasive cancers with the full combination, with an adjusted hazard ratio of 0.39. This was any invasive cancer, not metastatic cancer, and the comparison involved only four versus 12 cases.

Dr. Steve Horvath: The parent DO-HEALTH trial did not significantly improve its six primary clinical outcomes: blood pressure, lower-extremity function, cognition, nonvertebral fractures, or infections. The small epigenetic-clock changes are biomarkers, not proof of longer life or disease prevention.

Dr. Rhonda Patrick: It is reasonable to ask whether healthy behaviors compound over decades, but this trial followed older adults for three years. It did not test people in their 20s through 50s or show that the clock effects persist linearly for life.

Vitamin D deserves separate context. In DO-HEALTH, 2,000 IU per day did not change epigenetic clocks on its own. A Berlin BASE-II cohort found lower DNA-methylation age acceleration among deficient adults who chose supplementation compared with matched untreated deficient adults. That analysis was observational or quasi-interventional, not randomized, so it does not prove reversal of aging.

Baseline status matters when treating a documented deficiency, but vitamin D is not a universal anti-aging supplement. Dose should account for measured 25-hydroxyvitamin D, total intake, kidney and parathyroid conditions, medicines, and the risk of hypercalcemia.

Omega-3 safety also depends on dose and context. High-dose products can increase atrial-fibrillation risk in some high-risk patients and can affect bleeding. Product purity, oxidation, anticoagulants, and clinical indications matter. Exercise should match a person's strength, balance, and fall risk.

Dr. Steve Horvath: The evidence supports a modest omega-3 signal on selected aging biomarkers in this older Swiss cohort. It does not identify an exact universal supplement combination that slows biological aging.